[["index.html", "Portfolio Laurine Seelt 1 Introduction 1.1 This is the introduction to the Bookdown", " Portfolio Laurine Seelt Laurine Seelt 2022-04-30 1 Introduction 1.1 This is the introduction to the Bookdown 1.1.1 subheader "],["assignment-1.html", "2 Assignment 1 2.1 A 2.2 B 2.3 C 2.4 D 2.5 E 2.6 F 2.7 G 2.8 H 2.9 I 2.10 J 2.11 K", " 2 Assignment 1 This was the first assignment for our portfolio. 2.1 A 2.2 B Tidydata &lt;- read_excel(here(&quot;Data/Data_raw/CE.LIQ.FLOW.062_Tidydata.xlsx&quot;)) 2.3 C typeof(Tidydata$RawData) ## [1] &quot;double&quot; typeof(Tidydata$compName) ## [1] &quot;character&quot; typeof(Tidydata$compConcentration) ## [1] &quot;character&quot; RawData is double, dat is te begrijpen, het zijn getallen. CompName is een character, dat is ook te begrijpen. In die kolom staan de namen van de stofjes die zijn gebruikt. CompConcentration is een character, wat wel apart is. In die kolom staan de concentraties van de gebruikte stofjes, dus je zou verwachten dat dit een numerieke kolom zou zijn. 2.4 D Tidydata %&gt;% ggplot(aes(x = compConcentration, y = RawData, colour = compName, shape = expType)) + geom_point() 2.5 E De getallen worden geordend op basis van met welk getal ze beginnen, niet de daadwerkelijke grootte.Dus bijvoorbeeld 4,05x10-5 staat verder naar rechts dan 0,1 omdat 4,05x10-5 dus met een 4 begint. CompConcentration is een character kolom, dus ..? 2.6 F Tidydata$compConcentration &lt;- as.numeric(Tidydata$compConcentration) ## Warning: NAs introduced by coercion Tidydata %&gt;% ggplot(aes(x = (log10(compConcentration + 0.001)), y = RawData, colour = compName, shape = expType)) + geom_point() + geom_jitter(position = position_jitter(0.2)) ## Warning: Removed 6 rows containing missing values (geom_point). ## Warning: Removed 6 rows containing missing values (geom_point). 2.7 G C. Elegans die met Ethanol zijn behandeld. 2.8 H C. Elegans die met S-medium zijn behandeld. 2.9 I Om te analyseren of verschillende concentraties effect hebben op de hoeveelheid nakomelingen, zou ik aparte tabellen maken per stof (en per concentratie?). Dan kan je het gemiddelde en de standaard deviatie per stof en per concentratie berekenen. Ook kan je dan per stof een ANOVA test uitvoeren, om te kijken of het effect significant is. Dus 1. Aparte tabellen maken met de metingen per stof. 2. Het gemiddelde en de standaardeviatie berekenen voor elke concentratie van elke stof. 3. Een ANOVA test uitvoeren voor elke stof om te kijken of er dus inderdaad significante verschillen zijn in effect tussen de concentraties. Om te analyseren of de verschillende stoffen een andere curve/IC50 hebben, moet je per stof kijken naar het effect op de hoeveelheid nakomelingen. Daar kan je een grafiek van maken, met op de x-as de concentratie van de stof en op de y-as de hoeveelheid nakomelingen. 2.10 J Tidydata$compConcentration &lt;- as.numeric(Tidydata$compConcentration) Tibble_mean &lt;- Tidydata %&gt;% group_by(compName, compConcentration) %&gt;% summarize(mean = mean(RawData, na.rm = TRUE)) # Het gemiddelde van de negatieve controle, S-medium, is 85,9. Dat is dus de waarde waar de andere gemiddelden voor genormaliseerd moeten worden. Tibble_mean &lt;- Tibble_mean %&gt;% mutate(mean_norm = mean / 85.9) Tibble_mean %&gt;% ggplot(aes(x = (log10(compConcentration + 0.001)), y = mean_norm, colour = compName, shape = compName)) + geom_point() + geom_line()+ labs(title = &quot;The effect of different compounds on the amount of offspring&quot;, x = &quot;Compound concentration (log10 + 0.001)&quot;, y = &quot;Mean offspring, normalised&quot;) ## Warning: Removed 1 rows containing missing values (geom_point). ## Warning: Removed 1 row(s) containing missing values (geom_path). 2.11 K Omdat je dan duidelijker het effect kan zien van de verschillende stoffen en verschillende concentraties. De grafiek is veel overzichtelijker op deze manier. Ook kan je duidelijk per stof en per concentratie het verschil zien met de negatieve controle. "],["assignment-2.html", "3 Assignment 2 3.1 Part 1 3.2 Part 2", " 3 Assignment 2 This was assignment 2 for our portfolio. 3.1 Part 1 https://pubmed.ncbi.nlm.nih.gov/29324233/ Study purpose: 1 Data availability statement: 1 Data location: 1 Study location: 1 Author review: 7 Ethics statement: 0 Funding statement: 1 Code availability: 1 ? In this study, researchers investigated the heterologous effects of Bacillus Calmette-Gu√©rin (BCG) vaccination against other, non-related virus infections. It has been known for some time that BCG vaccination has positive heterologous effects against other virusses, but the exact immunological basis for this effect has never been examined in depth. The researchers in this study examined the genome-wide histone modifications that take place as a result of BCG vaccination, and also examined the functional changes in monocytes that take place after BCG vaccination. The effect of BCG vaccination on viral, serological and immunological parameters after administration of the Yellow Fever Vaccine was also examined. The method used for this study was ChIP-sequencing, to look at genome-wide changes in the distribution of H3K27ac. H3K27ac is a marker of active promoters and enhancers. This was done before BCG vaccination and one month after BCG vaccination. Correlation plots showed a clear distinction between the two kinds of samples. Most changes between the two kinds of samples were related to G-protein coupled receptors and protein kinases, which shows that BCG vaccination has a substantial effect on remodeling signal transduction molecules. The researchers also showed that the cytokine response to unrelated pathogens was enhanced one month after BCG vaccination. The heterologous T-cell response was also moderately enhanced after BCG vaccination. Next, this study looked at the difference in immune response to the Yellow Fever Vaccine between people who had had the BCG vaccination, and people who hadnt. People who had had the vaccine had a significantly lower viremia compared to people who had had the placebo vaccine. It was seen that mainly increased IL1-B and IL-10 production predicted a lower viremia in subjects who had had the BCG vaccine. 3.2 Part 2 "],["assignment-3.html", "4 Assignment 3", " 4 Assignment 3 This was the third assignment for our portfolio. "],["404.html", "Page not found", " Page not found The page you requested cannot be found (perhaps it was moved or renamed). You may want to try searching to find the page's new location, or use the table of contents to find the page you are looking for. "]]
